Ira Meyers, DPM
Podiatrist · Huntingdon Valley, PANPI 1235132200
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,738 of the $7,784 with a category attached, or 60.9%. 32 manufacturers reported payments, led by International Rehabilitative Sciences, Inc at 38.6% of the total. Reporting peaked in 2024 at $4,268 and has fallen 65.0% since, to $1,495 in 2025. Among podiatrist clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 167 payments — averaging $46.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- International Rehabilitative Sciences, Inc$3K
- Organogenesis Inc.$881
- Paratek Pharmaceuticals, Inc.$853
- Amgen$509
- Averitas Pharma Inc.$502
- Smith+Nephew$305
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,73861%
- Education$1011%
- Other$2,94538%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| International Rehabilitative Sciences, Inc | 2 | $3,002 |
| Organogenesis Inc. | 29 | $881 |
| Paratek Pharmaceuticals, Inc. | 28 | $853 |
| Amgen(2 entities) | 30 | $509 |
| Averitas Pharma Inc. | 12 | $502 |
| Smith+Nephew | 11 | $305 |
| Nevro Corp. | 6 | $236 |
| Convatec Inc. | 8 | $230 |
| Stryker | 3 | $145 |
| Boston Scientific | 2 | $125 |
| Biopro, Inc. | 1 | $120 |
| AstraZeneca | 1 | $107 |
| Orthofix Medical, Inc. | 4 | $81 |
| Treace Medical Concepts, Inc. | 1 | $78 |
| Vertex | 3 | $71 |
| Solventum Corporation | 3 | $70 |
| Bioventus LLC | 2 | $56 |
| Pacira Pharmaceuticals Incorporated | 2 | $50 |
| IBSA Pharma Inc. | 2 | $48 |
| Paladin Technology Solutions | 2 | $40 |
| Next Science LLC | 2 | $40 |
| Melinta Therapeutics, LLC | 2 | $38 |
| Hartmann USA, Inc. | 1 | $29 |
| Kerecis Limited | 1 | $27 |
| Heron Therapeutics, Inc. | 2 | $21 |
| KCI USA, Inc. | 1 | $21 |
| Fidia Pharma USA Inc. | 1 | $19 |
| Zimmer Biomet | 1 | $18 |
| Johnson & Johnson | 1 | $18 |
| Urgo Medical North America, LLC | 1 | $18 |
| Acera Surgical, Inc. | 1 | $16 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RS 4i Plus Sequential Stimulator$2,945
- RS-FBG, RS LBG GARMENT$2,945
- Qutenza$231
- Affinity$224
- NUZYRA$224
- Omnia$139
- PURAPLY WOUND MATRIX$121
- Apligraf$121
- COLLAGENASE SANTYL$119
How this compares
$7,784 in reported general payments places this provider in the 90th percentile of 445 podiatrist providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SantylCollagenase Clostridium Hist. | 12 | $3,883 |
| Pregabalin | 39 | $711 |
| Pentoxifylline | 17 | $483 |
| Cephalexin | 39 | $236 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 20 | $183 |
| Mupirocin | 23 | $131 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 22 | $112 |
| Methylprednisolone | 24 | $93 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 11 | $41 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Smith+NephewSantyl | $305 | $3,88312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 445 podiatrist providers in Pennsylvania.
Other podiatrist in Huntingdon Valley
- Mark HofbauerBelle Vernon$1.1M
- Daniel PerezPhiladelphia$434K
- Christopher BarrettChester$229K
- Alan CatanzaritiPittsburgh$80K
- John StarinskiPen Argyl$74K
- Kwasi KwaaduPhiladelphia$65K
- Luke CicchinelliPhiladelphia$62K
- James McGuirePhiladelphia$60K
- John SchelandClarks Summit$54K
- John LapelusaYork$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.